Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 16/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065963 | 1.00 | P2RY12 (0.51) | P2RY12USP2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL2066541 | 0.83 | P2RY12 (0.57) | P2RY12USP2 | |
| SCHEMBL2066191 | 0.83 | P2RY12 (0.52) | P2RY12ALDH1A1TSHR | |
| SCHEMBL2068267 | 0.83 | P2RY12 (0.52) | P2RY12ALDH1A1TSHR | |
| SCHEMBL2066447 | 0.81 | P2RY12 (0.62) | P2RY12CYP2C9 | |
| SCHEMBL10074050 | 0.75 | P2RY12 (0.53) | P2RY12KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL2065766 | 0.75 | P2RY12 (0.53) | P2RY12KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL2065702 | 0.75 | P2RY12 (0.53) | P2RY12CYP2C9 | |
| SCHEMBL5002843 | 0.75 | P2RY12 (0.53) | P2RY12KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL2065967 | 0.74 | P2RY12 (0.50) | P2RY12CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148385-B2 | Substituted [1,2,3] triazolo[4,5-d]pyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-8148385-B2 | Substituted [1,2,3] triazolo[4,5-d]pyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20080312257-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312257-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312257-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | P2RY12, P2RY1, P2RY2 | P2RY12 1/4885USP2 4236/4885KDM4E 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.